BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-10-30 15:38 |
BerGenBio ASA: Primary Insider notification
|
English | 673 bytes | ||
| 2020-10-28 15:39 |
BerGenBio ASA: Primary Insider notification
|
English | 674 bytes | ||
| 2020-10-27 15:57 |
Flagging
|
Norwegian | 537 bytes | ||
| 2020-10-23 05:00 |
BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020
|
English | 71.8 KB | ||
| 2020-10-23 05:00 |
BERGENBIO VIRTUAL R&D DAY - 06 NOVEMBER 2020
|
English | 6.3 KB | ||
| 2020-10-21 09:36 |
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTIN…
|
English | 44.6 KB | ||
| 2020-10-21 09:36 |
BerGenBio bekrefter første pasient registrert i fase-II studie av bemcentinib s…
|
Norwegian | 44.1 KB | ||
| 2020-10-21 09:36 |
BERGENBIO CONFIRMS FIRST PATIENT ENROLLED IN PHASE II TRIAL ASSESSING BEMCENTIN…
|
English | 6.0 KB | ||
| 2020-10-21 09:36 |
BerGenBio bekrefter første pasient registrert i fase-II studie av bemcentinib s…
|
Norwegian | 6.0 KB | ||
| 2020-10-15 05:00 |
BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMC…
|
English | 41.4 KB | ||
| 2020-10-15 05:00 |
BerGenBio presenterer kliniske translasjonsdata fra den pågående fase-II kombin…
|
Norwegian | 45.4 KB | ||
| 2020-10-15 05:00 |
BERGENBIO TO PRESENT CLINICAL TRANSLATIONAL DATA FROM THE ONGOING PHASE II BEMC…
|
English | 5.4 KB | ||
| 2020-10-15 05:00 |
BerGenBio presenterer kliniske translasjonsdata fra den pågående fase-II kombin…
|
Norwegian | 5.5 KB | ||
| 2020-10-14 05:00 |
BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32[nd] ENA SYMPOSIUM
|
English | 43.7 KB | ||
| 2020-10-14 05:00 |
BerGenBio presenterer data om anti-AXL antistoff tilvestamab på 32[nd] ENA symp…
|
Norwegian | 43.7 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
